Francesca Barone
Chief Tech/Sci/R&D Officer bei CANDEL THERAPEUTICS, INC.
Vermögen: 294 918 $ am 31.03.2024
Profil
Francesca Barone is currently the Chief Scientific Officer at Candel Therapeutics, Inc. She previously worked as the Director-laboratories at the Institute of Translational Medicine.
From 2010 to 2019, she was an Associate Professor at the University of Birmingham.
In 2019, she became the Head-Experimental Medicine at Senda Biosciences, Inc. Dr. Barone holds a doctorate degree from Sapienza University of Rome and King's College London.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.11.2023 | 186 657 ( 0,65% ) | 294 918 $ | 31.03.2024 |
Aktive Positionen von Francesca Barone
| Unternehmen | Position | Beginn |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.11.2020 |
Ehemalige bekannte Positionen von Francesca Barone
| Unternehmen | Position | Ende |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.11.2020 |
| University of Birmingham | Corporate Officer/Principal | 01.05.2019 |
| Institute of Translational Medicine | Corporate Officer/Principal | - |
Ausbildung von Francesca Barone
| Sapienza University of Rome | Doctorate Degree |
| King's College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Institute of Translational Medicine |
